LivaNova gains FDA premarket approval for aura6000 for...

2026-03-19 10:58:23 ET More on LivaNova LivaNova: Excellent Performer, But Too Expensive In 2026 (Rating Downgrade) LivaNova PLC (LIVN) Q4 2025 Earnings Call Transcript LivaNova PLC 2025 Q4 - Results - Earnings Call Presentation LivaNova outlines 6%-7% revenue growth for 2026 as core businesses expand and OSA launch nears LivaNova PLC Non-GAAP EPS of $0.86 beats by $0.05, revenue of $360.9M beats by $6.59M Read the full article on Seeking Alpha For further details see: LivaNova gains FDA premarket approval for aura6000 for sleep apnea